The skin-specific mechanisms of GHK-Cu include stimulation of Type I and Type III procollagen synthesis, increased production of dermatan sulfate and other glycosaminoglycans, activation of the enzyme lysyl oxidase (which cross-links newly formed collagen), reduction of matrix metalloproteinase-1 (MMP-1, collagenase) activity, and anti-inflammatory suppression of TNF-alpha-induced IL-6 secretion
While sub-threshold concentrations of each ligand alone did not alter basal spinogenesis, combined sub-threshold concentrations of 30 " M Dihexa and 2.5 ng/ml HGF or 10 " 13 M Nlel -AnglV and 2.5 ng/ml of HGF produced a near ceiling effect, similar to biological responsive doses of each ligand alone (Figure 1 1 A and B)
April 2026 Category 2 Update On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn
Future studies should investigate the biochemical and physiological mechanisms that underlie the persistence of the adverse sexual side effects to determine why a subset of patients is afflicted with such persistence or irreversible adverse effects
In response, Koniver began offering a peptide that differed by a single amino acid